The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial

Study Design

Subject Type

Human

Trial Design

Double-Blind, Randomised, Controlled

Trial Duration

56 days

Participants

20 (20 completed)

Age Range

28-49 years

Mechanisms

Intervention(s)			Outcome		Method		Effect	Description
Rucinol			Melanin		Mexameter		🠫	Sign in to read for free
Sign in to read for free

Side Effects

Study Summary